Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue , 2015, Pages

  Gangadhar, Tara C ^a   Hamid, Omid ^b   Smith, David C ^c   Bauer, Todd M ^d   Wasser, Jeffrey S ^e   Luke, Jason J ^f   Balmanoukian, Ani S ^b   Kaufman, David R ^g   Zhao, Yufan ^h   Maleski, Janet ^h   Leopold, Lance ^h   Gajewski, Thomas F ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Angeles Clinic and Research Institute   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; EPACADOSTAT; PEMBROLIZUMAB;

ADVANCED CANCER; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IC50; MELANOMA; MUCOSA INFLAMMATION; NAUSEA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RENAL CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME;

EID: 84995684655     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-3-S2-O7     Document Type: Article

References (1)

1. Gibney GT, et al: European Cancer Congress. 2015, [abstract 511]